Discover how automated insulin delivery (AID) benefits type 1 diabetes and ongoing trials assessing the impact of AID systems on type 2 diabetes management.

Orforglipron, Eli Lilly's once-daily oral GLP-1 receptor agonist, is being studied in ongoing clinical trials for obesity and type 2 diabetes. Data shows A1C reductions...

The T1DEXI study sheds light on the impact of exercise on type 1 diabetes, including how to manage hypoglycemia and hyperglycemia. In addition, here are some practical...

Explore the VITAL-CGM trial, which investigates if using a combination of CGM and WeightWatchers can lower A1C in people with type 2 diabetes.

Descubre las razones por las cuales los hispanos tienen un riesgo elevado de sufrir diabetes tipo 2 y encuentra consejos de expertos para prevención y manejo de la...

Halloween can be a tricky holiday to navigate. Here are some ways to make trick or treating safe for people with diabetes and some other fun activities to do that don't...

Omnipod 5 users will soon be able to control their AID system through a free iPhone app available in the new year. Like the Android app, iPhone users will be able to...

In case you missed them, here are our top stories from October 2023 that cover upcoming therapies, groundbreaking research, and more.

Evelyn Oberdorfer, 65, is a bodybuilder and half-marathon runner. She credits building her resilience from managing the highs and lows of type 1 diabetes since childhood.

While some affirm the health benefits of caffeine, like improving insulin sensitivity and blood sugar, research is mixed on whether it's detrimental for people with...

Join a study investigating BMF-219, a menin inhibitor that could stimulate healthy beta cell regeneration and potentially slow diabetes progression.

Medtronic unveils Simplera, the latest CGM approved in Europe for people with diabetes ages two and older. A sleek, disposable device, Simplera rivals the Dexcom G7 and...

Researchers find automated insulin delivery (AID) systems, the MiniMed 780G and Omnipod 5, showed significant improvement in time in range for everyday users. This real-...

Ongoing hostilities and violence across the world leave people with diabetes in crisis and without access to essential resources. What can be done to help?

Determining ideal carbohydrate intake for those with type 1 diabetes remains complex. Two studies at EASD 2023 highlight the benefits of a plant-based diet and...

A third patient with type 1 diabetes becomes insulin-independent after VX-880 stem cell treatment. Presented at the 2023 EASD conference, Vertex's early-phase trial...

The newest study of once-weekly insulins showed that insulin icodec led to similar reductions in A1C and similar time in range compared to once-daily Tresiba (degludec).

The FDA is cautioning people that the diabetes medication Ozempic – commonly prescribed off-label for weight loss – may be linked to a rare but severe side effect.

Here are our top stories from September 2023. This month’s best stories cover a wide variety of topics like upcoming therapies, new research findings, and more.

Early research finds that people with type 1 diabetes who started taking Ozempic (semaglutide) were able to reduce their insulin dose. This research suggests potential...